StemCells (STEM) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
StemCells, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
March 16, 2015 4:05 PM EDTNEWARK, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2014.
"We achieved three significant clinical translation milestones in 2014: the completion of enrollment in two Phase I/II studies and initiation of the first of two planned, multicenter Phase II proof of concept studies using our proprietary human neural stem cell platform," said Martin McGlynn, President... More
